Skip to main content
TELO
NASDAQ Life Sciences

Telomir Flags Going Concern Doubt, Cash Only Through Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.05
Mkt Cap
$72.214M
52W Low
$0.888
52W High
$2.091
52W Position info
18% above low
Off High info
50% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TELO sits 18% above its 52-week low of $0.888.

Summary

Telomir Pharmaceuticals' Q2 10-Q raises substantial doubt about its ability to continue as a going concern, with cash runway only through Q1 2027 and a $3.5M+ legal claim from its former CEO's estate.


Key Events · Earnings and Guidance · TELO

  • Going Concern Warning

    Management states substantial doubt about the company's ability to continue as a going concern for 12 months from the issuance date, citing insufficient cash and ongoing losses.

  • Cash Runway Through Q1 2027

    Cash of $5.2M as of June 30, 2026, with management expecting funds to support operations only through the first quarter of 2027.

  • Legal Claim from Former CEO Estate

    Estate of Christopher Columbus Chapman, Jr. filed a complaint on June 5, 2026, claiming damages in excess of $3.5M for delayed transfer of restricted stock. No liability recorded.

  • TELI Merger Completed

    Merger closed April 22, 2026, issuing 34,389,710 shares. Recorded a $46.1M deemed dividend, reducing net loss attributable to common stockholders to $48.8M for H1 2026.


Analysis · TELO · Life Sciences

Telomir's Q2 10-Q raises substantial doubt about its ability to continue as a going concern, with only $5.2M in cash and a runway expected to last through the first quarter of 2027. The company also disclosed a $3.5M+ legal claim from the estate of its former CEO. While the TELI merger consolidated global rights to Telomir-Zn, the accounting treatment produced a $46.1M deemed dividend that wiped out most of the equity value of the transaction. The company is seeking additional capital, but the going concern warning and legal overhang are material risks for a micro-cap biotech with no revenue.

At the time of this filing, TELO was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.2M. The 52-week trading range was $0.89 to $2.09. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TELO - Latest Insights

TELO
Aug 10, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $1.05 info
Change: -$0.150 (-12%) info
Market Cap: $72.214M info
TELO
Aug 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.05 info
Change: -$0.140 (-12%) info
Market Cap: $72.214M info
TELO
Jun 15, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $1.05 info
Change: -$0.2155 (-17%) info
Market Cap: $72.214M info
TELO
Jun 15, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $1.05 info
Change: -$0.200 (-16%) info
Market Cap: $72.214M info
TELO
Jun 08, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.28
Real-time Price: $1.05 info
Change: -$0.230 (-18%) info
Market Cap: $72.214M info